Ind-Swift Laboratories Limited (NSE:INDSWFTLAB)
109.63
+2.78 (2.60%)
Jan 23, 2026, 3:30 PM IST
Ind-Swift Laboratories Revenue
Ind-Swift Laboratories had revenue of 1.53B INR in the quarter ending September 30, 2025, with 1,176.68% growth. This brings the company's revenue in the last twelve months to 5.72B, down -22.98% year-over-year. In the fiscal year ending March 31, 2025, Ind-Swift Laboratories had annual revenue of 5.62B, down -67.13%.
Revenue (ttm)
5.72B
Revenue Growth
-22.98%
P/S Ratio
1.56
Revenue / Employee
4.59M
Employees
1,246
Market Cap
8.95B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 5.62B | -11.47B | -67.13% |
| Mar 31, 2024 | 17.09B | 4.93B | 40.56% |
| Mar 31, 2023 | 12.16B | 1.63B | 15.48% |
| Mar 31, 2022 | 10.53B | 1.46B | 16.12% |
| Mar 31, 2021 | 9.07B | 1.07B | 13.44% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 17.25B |
| Nectar Lifesciences | 16.70B |
| Solara Active Pharma Sciences | 12.06B |
| Windlas Biotech | 8.30B |
| Orchid Pharma | 8.21B |
| Sigachi Industries | 5.09B |
| Beta Drugs | 3.86B |
| Jagsonpal Pharmaceuticals | 2.82B |